Can the protocol be electronically signed?

Yes. Electronic signatures are legally valid in the United States under the ESIGN Act (15 U.S.C. §7001) and UETA in states that adopted it. Ensure consent to electronic records where consumer-facing protections apply.

Is IRB approval required for the final protocol?

Yes when human subjects research is involved. Final protocol changes and closeout often require IRB review under 45 CFR Part 46; follow institutional procedures for reporting and closure.

Do electronic signatures satisfy institutional requirements?

Many institutions accept e-signatures if platform controls meet authentication, audit trail, and record retention standards; verify with institutional compliance and legal offices.

How long must protocol records be retained?

Retention varies by law and sponsor requirements; HIPAA mandates six years for certain records (45 CFR §164.530(j)); follow sponsor and institutional policies for longer retention as required.

What authentication level is recommended?

Use email + SMS or stronger multi-factor authentication for external signers; advanced identity proofing is advisable when signatures affect regulatory submissions or legal obligations.

How do I correct a signed final protocol?

If changes are substantive, prepare an amendment with signatures and version history; minor clerical corrections may require an erratum or institutional procedures to document the change.

Electronic Signature
Templates
Miscellaneous
Research Final Study Protocol

Research Final Study Protocol

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

RESEARCH FINAL STUDY PROTOCOL

This Research Final Study Protocol (the "Protocol") is entered into between:

Sponsor Name:

Institution Name:

WHEREAS

WHEREAS, Sponsor Name: has an interest in conducting the research study described in this Protocol; and

WHEREAS, Institution Name: possesses the facilities and qualified personnel to conduct the study in accordance with applicable laws, regulations, and recognized standards of good clinical practice; and

WHEREAS the parties desire to set forth the final, binding Protocol for the conduct, management, monitoring, data handling, and reporting of the study as described below.

PROTOCOL IDENTIFICATION

Protocol Title:

Study ID / Protocol Number: Version: Effective Date:

KEY CONTACTS

Principal Investigator Site Address Sponsor Contact

SCOPE OF WORK

The Institution shall perform the study activities, enroll subjects, collect data, and conduct analyses as set forth in the scope below. The Scope of Work describes deliverables, timelines, and responsibilities allocated between the parties.

Detailed Scope of Work

STUDY OVERVIEW

Background and Rationale Primary Objective Secondary Objectives

STUDY DESIGN

Design Summary Study Population (Inclusion / Exclusion)

Planned Sample Size: Primary Endpoint(s):

Study Procedures and Schedule

DATA MANAGEMENT AND STATISTICAL ANALYSIS

Data Collection and Source Documents Statistical Analysis Plan (Summary)

SAFETY, MONITORING, AND REPORTING

Safety Monitoring and Reporting Requirements Data Safety Monitoring Board (if applicable)

PAYMENT TERMS

Total Contract Amount:

Payment Schedule

Late Payment Fee:

TERM AND TERMINATION

Study Start Date: Anticipated End Date:

Termination and Notice

CONFIDENTIALITY

Each party shall hold confidential and shall not disclose to any third party any Confidential Information disclosed by the other party, except as expressly permitted by this Protocol or required by law. Confidential Information includes patient-level data, proprietary protocols, unblinded analysis, and any other non-public information identified as confidential.

INTELLECTUAL PROPERTY AND PUBLICATION

AMENDMENTS

Any amendment to this Protocol shall be in writing and signed by authorized representatives of both parties. Amendments affecting subject safety or consent procedures shall require prior Institutional Review Board or Ethics Committee approval where applicable.

GOVERNING LAW

This Protocol shall be governed by and construed in accordance with the laws of the state or jurisdiction where the Institution is located. Any dispute arising from this Protocol shall be resolved in the competent courts of that jurisdiction, unless the parties agree otherwise in writing.

ENTIRE AGREEMENT

This Protocol, together with any referenced schedules, appendices, and signed amendments, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, and communications, whether written or oral.

SIGNATURES

Sponsor (Printed Name):

By:

Date:

Institution (Printed Name):

By:

Date:

What the Research Final Study Protocol Is

A Research Final Study Protocol is the definitive, comprehensive document that describes the final design, objectives, methods, and governance for a completed or closing clinical or nonclinical study. It consolidates background, finalized procedures, inclusion/exclusion criteria, endpoints, statistical analysis plan, monitoring and safety provisions, data management approaches, and post-study obligations. The protocol provides the authoritative reference for regulatory submissions, sponsor oversight, ethics review closure, and archival. Preparing a clear, accurate final protocol supports audit readiness, data reproducibility, and transparent reporting of study results.

Why a Robust Final Protocol Matters

A well-drafted Research Final Study Protocol documents agreed methods, protects participant welfare, and supports regulatory and ethical compliance. It is the single source of truth for analyses, reporting, and post-study obligations.

Who Prepares and Relies on the Final Protocol

Multiple stakeholders prepare, review, or use the Research Final Study Protocol during study closeout and reporting phases.

Principal investigators and study teams responsible for finalizing methods and safety reporting.
Institutional Review Boards (IRBs) and ethics committees reviewing final procedures and participant protections.
Regulatory affairs and sponsor representatives preparing submissions and reconciliation documents.

Clear ownership and signatory authority reduce delays during submission, audit, and archiving processes.

Step-by-Step: Finalizing the Protocol

Follow this sequence to complete and close out the research protocol consistently across stakeholders.

01

1. Consolidate: Gather final datasets, CRFs, and amendments for reconciliation.
02

2. Verify: Confirm endpoints, statistical code, and analysis reproducibility.
03

3. Obtain Approvals: Secure signatures from PI, sponsor official, and institutional authority.
04

4. Archive: Store the final protocol and associated data per retention rules.

How Electronic Completion and Routing Works

Electronic workflows streamline approvals and preserve an auditable trail; this outlines a typical routing pattern for the final protocol.

Upload: Sponsor or study coordinator uploads final protocol document.
Assign Fields: Place signature, date, and initials fields for required signers.
Route: Set signer order (PI → Sponsor → Institutional Official).
Complete: System captures timestamps, IPs, and audit evidence.

Digital Workflow Settings for Protocol Execution

Recommended workflow settings reduce signer friction and strengthen authentication where required.

Field	Configuration
Signer Order	Sequential routing by role
Authentication	Email + SMS code for external signers
Audit Trail	Enable full event log retention
Archival Format	PDF/A with embedded audit certificate

Technical and Compliance Requirements for eSubmission

Ensure the signing platform supports required authentication, audit trails, and records retention before e-submission.

Authentication: Support for email, SMS, and advanced signer verification
Audit Trail: Immutable event log with timestamps and IP data
Formats: Export signed files as PDF/A and XML metadata

Verify platform certifications (HIPAA BAA if PHI present, SOC 2 Type II, ESIGN/UETA compliance) and retention export capabilities before relying on electronic records.

Required Protocol Metadata and Compliance Flags

Protocol ID: Unique trial identifier

IRB Approval: Approval number and date

HIPAA Flag: Indicate PHI presence

Data Location: Repository and format

Retention Period: Retention timeframe

Signatory List: Named required signers

Consequences of an Incomplete or Incorrect Protocol

Regulatory Action: IRB suspension or hold

Data Rejection: Analyses excluded from regulatory review

Legal Liability: Sponsor or PI exposure

HIPAA Breach: Civil penalties and notification

Publication Delay: Journal rejection or correction

Financial Penalty: Fines from agency enforcement

Common Preparation Pitfalls to Avoid

Missing or inconsistent protocol identifiers that prevent linking datasets and registry entries.
Unclear endpoint definitions leaving room for post hoc changes and audit findings.
Failure to document deviations, amendments, or statistical code used for final analyses.
Inadequate consent or PHI handling language that triggers HIPAA or IRB remediation.

Key Deadlines and Submission Timing

Typical deadlines depend on IRB and sponsor schedules; below are common time-sensitive items to track during closeout.

Final Protocol Sign-off:

Complete signatory approvals before data lock

IRB Closeout Notice:

Submit closeout to IRB within required local window

Registry Update:

Update trial registry with final results per policy

Data Lock:

Freeze datasets prior to statistical finalization

Final Report:

Submit final study report to sponsor and regulators

Sequential Milestones from Draft to Archive

A numbered sequence helps teams coordinate approvals, data reconciliation, and archiving during protocol closeout.

01

Draft Final Protocol

Consolidate amendments and analysis plans for review.

02

Internal Review

Sponsor and statistician confirm methods and outputs.

03

External Approvals

Secures IRB and institutional sign-offs required for closure.

04

Archive & Publish

Store records and submit registry or journal outputs.

Core Elements Every Professional Final Protocol Should Contain

Including these elements reduces review iterations and demonstrates adherence to regulatory and ethical expectations.

Study Overview

Concise rationale, objectives, and finalized hypotheses, including any changes from the original protocol and a clear statement of why changes were necessary.

Methods Summary

Finalized procedures for enrollment, interventions, blinding, and data collection with sufficient detail to permit replication of primary analyses.

Statistical Plan

Prespecified statistical methods, handling of missing data, sensitivity analyses, and software/code references for reproducibility.

Safety Monitoring

Adverse event definitions, reporting timelines, data monitoring committee decisions, and any safety-driven protocol modifications.

Data Management

Data cleaning rules, derivations, metadata, deidentification strategy, and authorized access control descriptions.

Regulatory Record

Signatures, version history, IRB correspondence, registry updates, and submission records for audits and inspections.

Comparing eSignature Pricing and Features for Protocol Signing

Vendor pricing and core features vary; the table below summarizes starting price, bulk send, audit trail, and HIPAA support for common solutions.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	Yes, 7-day trial	No	No	No	No
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Real-World Examples of Protocol Execution

Two real customer scenarios illustrate how digital signing and rigorous protocol documentation reduce friction and support compliance.

Optica Ventures LLC

Optica consolidated execution for multiple study sites into a single protocol approval process to reduce repeated signatures and version confusion.

They routed the final protocol to PI, sponsor, and institutional official in sequence to maintain a clear audit trail.
The team reported fewer version-control errors and faster IRB closeouts while preserving required records for audits.

Fertility Centers of Illinois

The center needed consistent signed protocols across clinics to support compliance and patient safety during multi-site studies.

They standardized signatory roles and used electronic routing to capture timestamps for each signer.
This approach improved traceability for inspections and ensured that final study documents were uniformly archived and retrievable.

How the Research Final Study Protocol Differs from Related Documents

Compare the final protocol with commonly confused or adjacent documents to clarify scope and intended use.

Document Type	Primary Purpose	Typical Signers
Final Study Protocol	defines final methods	pi, sponsor, institutional official
Statistical Analysis Plan	details analysis only	statistician, pi
Informed Consent Form	documents participant consent	pi, participant
Clinical Trial Agreement	defines legal terms	sponsor, institution

Practical Tips for Accurate and Efficient Completion

Adopt these practices to shorten review cycles and lower the risk of audit findings or regulatory queries.

Version Control

Maintain a single controlled document repository and use an immutable version history; track changes and approvals to prevent parallel drafts from circulating.

Clear Signatory Roles

Define who signs which sections and their authority; list names, titles, and institutional affiliations to avoid ambiguity during audits.

Preconfigured Workflow

Use templates that preplace signature and date fields, enforce required fields, and apply conditional logic to reduce manual steps.

Preserve Evidence

Store signed PDFs with embedded audit certificates and retain metadata to support reproducing the signing event for inspectors.

Key Signatory Roles and Responsibilities

Principal Investigator

The PI is responsible for study conduct, accuracy of the protocol content, and attesting to compliance with ethical and regulatory obligations regarding participant safety and data integrity.

Institutional Official

An authorized institutional representative confirms institutional resources, legal acceptance of study terms, and oversight provisions; their signature permits institutional accountability.

Frequently Asked Questions About the Research Final Study Protocol

Answers to common questions on execution, signatures, and retention for the Research Final Study Protocol.

Need help? Contact support

Can the protocol be electronically signed?
Yes. Electronic signatures are legally valid in the United States under the ESIGN Act (15 U.S.C. §7001) and UETA in states that adopted it. Ensure consent to electronic records where consumer-facing protections apply.
Is IRB approval required for the final protocol?
Yes when human subjects research is involved. Final protocol changes and closeout often require IRB review under 45 CFR Part 46; follow institutional procedures for reporting and closure.
Do electronic signatures satisfy institutional requirements?
Many institutions accept e-signatures if platform controls meet authentication, audit trail, and record retention standards; verify with institutional compliance and legal offices.
How long must protocol records be retained?
Retention varies by law and sponsor requirements; HIPAA mandates six years for certain records (45 CFR §164.530(j)); follow sponsor and institutional policies for longer retention as required.
What authentication level is recommended?
Use email + SMS or stronger multi-factor authentication for external signers; advanced identity proofing is advisable when signatures affect regulatory submissions or legal obligations.
How do I correct a signed final protocol?
If changes are substantive, prepare an amendment with signatures and version history; minor clerical corrections may require an erratum or institutional procedures to document the change.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now